Fluorescence Detection of Bladder Tumors with 5-Amino-Levulinic Acid

Riedl, Claus R.; Plas, Eugen; Pflüger, Heinz

doi:10.1089/end.1999.13.755

Cited by 53 publications

(48 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In two 72,78 of these studies the whole patient population (n = 102) had a suspicion of bladder cancer and in three 51,58,84 the whole population had previously diagnosed bladder cancer (n = 117). The remaining eight studies 50,52,54,56,67,73,76,85 did not report this information. In total, 18 50,53,54,56,58,59,[61][62][63]67,[70][71][72][73]77,78,84,85 (67%) of 27 studies used 5-ALA as the photosensitising agent, five 57,60,65,66,81 (19%) used HAL, two 52,76 (7%) used hypericin and two 51,80 used either 5-ALA or HAL but did report the number of patients receiving each agent.…”

Section: Figurementioning

confidence: 99%

“…Sixteen studies 50,51,53,56,[59][60][61][62][63]65,71,76,77,80,81,85 gave details of when they took place, with an earliest start date of February 1994 63 and latest end date of March 2006. 51 Nine studies took place in Germany, 54,56,58,61,70,71,80,84,85 Switzerland, 63 France, 72 Austria, 73 Poland, 78 South Korea 62 and China, 77 and four had multinational Germany/the Netherlands, 66 Germany/USA 67 and Switzerland/Norway/Sweden/Germany. 65 The four RCTs reporting recurrence/progression enrolled 709 participants, of whom 544 were included in the analysis.…”

Section: Figurementioning

confidence: 99%

“…The exception to this was the study by Koenig and colleagues,67 in which 55 patients were included but only 49 reported in the analysis. In 81% (22/27) of studies 50,[52][53][54]56,[58][59][60][61][62][63][65][66][67][70][71][72][73][76][77][78]84 a clear definition of what was considered to be a positive result was provided. In 96% (26/27) of studies it was unclear whether the same clinical data were available when the PDD test results were interpreted as would be available when the test was used in practice, the exception being the study by Ehsan and colleagues, 54 which stated that a detailed review of personal medical history was conducted for each patient before PDD.…”

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

“…In this context clinical data were defined broadly to include any information relating to the patient such as age, gender, presence and severity of symptoms, and other test results. In 59% (16/27) of studies 50,53,54,56,58,60,67,[70][71][72][73]77,78,81,84,85 it was unclear whether the reference standard results were interpreted without knowledge of the results of the PDD test. All of the studies were judged to suffer from incorporation bias in that PDD was not considered to be independent of the reference standard test as the biopsies used for the reference standard were obtained via the PDD procedure.…”

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

“…Five studies 65,66,73,80,81 comparing PDD with WLC and enrolling 386 people, with 370 included in the analysis, provided sufficient information to allow their inclusion in the pooled estimates for patientlevel analysis. In four studies, 65,66,80,81 of 318 patients included in the analysis, 131 (41%) had symptoms suggestive of bladder cancer and 187 (59%) had a history of non-muscle-invasive bladder cancer.…”

Section: Patient-level Analysismentioning

confidence: 99%

See 4 more Smart Citations

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

251

207

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. F...

show abstract

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

Section: Figure 8 Summary Of Quality Assessment Of Rcts Reporting Recmentioning

confidence: 99%

Section: Patient-level Analysismentioning

confidence: 99%

See 3 more Smart Citations

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

251

207

View full text Add to dashboard Cite

show abstract

Comparison between intravesical and oral administration of 5‐aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer

Inoue

Fukuhara²,

Shimamoto³

et al. 2011

Cancer

116

View full text Add to dashboard Cite

BACKGROUND: This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer. METHODS: Of all 210 cases, 75 underwent PDD with intravesically applied ALA, and 135 cases underwent PDD with orally applied ALA. Diagnostic accuracy was evaluated by comparing the level on images of ALA-induced fluorescence with the pathological result. PDD-TURBT was performed in 99 completely resectable cases corresponding to 210 ALA-PDD cases. To evaluate the abilities of PDD-TURBT, survival analysis regarding intravesical recurrence was retrospectively compared with the historical control cases that underwent conventional TURBT. RESULTS: The diagnostic accuracy and capability of ALA-PDD were significantly superior to those of conventional endoscopic examination. Moreover, 72.1% of flat lesions, including dysplasia and carcinoma in situ, could be detected only by ALA-PDD. The recurrence-free survival rate in the cases that underwent PDD-TURBT was significantly higher than that of conventional TURBT. Moreover, multivariate analysis revealed that the only independent factor contributing to improving prognosis was PDD-TURBT (hazard ratio, 0.578; P ¼ .012). Regardless of the ALA administration route, there was no significant difference in diagnostic accuracy, ability of PDD, or recurrence-free survival. All procedures were well tolerated by all patients without any severe adverse events. CONCLUSIONS: This multicenter study is likely to be biased, because it is limited by the retrospective analysis. This study suggests that regardless of the ALA administration route, ALA-PDD and PDD-TURBT are remarkably helpful in detection and intraoperative navigation programs.

show abstract

Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: Implication for whole bladder wall photodynamic therapy

Kamuhabwa

Cosserat-Gérardin

Didelon

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

In a recent clinical study, we reported a selective uptake of hypericin in superficial bladder tumors. The results suggested that hypericin, a potent photosensitizer, could be used not only for diagnosis but also for photodynamic therapy (PDT) of superficial bladder tumors. In the present study, we investigated the biodistribution of hypericin in an orthotopic rat bladder tumor model by assessing the extent of hypericin penetration and the kinetics of accumulation into rat bladder tumors and normal bladder wall. Hypericin (8 or 30 M) was instilled into the bladder via the catheter for 1, 2 or 4 hr. The fluorescence of hypericin in the bladder tumors and normal bladder was documented using fluorescence microscopy. In situ quantification of hypericin fluorescence in the tumor or normal bladder was performed using the laserinduced fluorescence technique. There was much more hypericin fluorescence in the tumor than in the normal bladder, with the tumor-to-normal-bladder ratio mounting to 12:1 after 4 hr of hypericin (30 M) instillation. Moreover, hypericin was retained in the tumor for at least 1 hr before it was gradually lost from the tissue. Microscopically, the fluorescence of hypericin was restricted to the urothelial tumor and normal urothelium without fluorescence in the submucosa and the muscle layers. Subsequently no hypericin was detected in plasma, indicating that under these conditions systemic side effects should not be expected. Because the conditions used in this study were similar to those used in our previous clinical study, it is therefore likely that whole bladder wall PDT in the clinic under these conditions will produce selective urothelial tumor destruction without causing damage to the underlying muscle layers.

show abstract

Fluorescence Detection of Bladder Tumors with 5-Amino-Levulinic Acid

Abstract: Fluorescence diagnosis with ALA may become a standard procedure for bladder tumor detection and resection, especially in endoscopically difficult situations (carcinoma in situ, multifocal tumors, multiple prior resections, or previous drug instillation therapy).

Cited by 53 publications

References 9 publications

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Comparison between intravesical and oral administration of 5‐aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer

Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: Implication for whole bladder wall photodynamic therapy

Contact Info

Product

Resources

About